2016
DOI: 10.1158/1538-7445.am2016-3220
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR

Abstract: Activation of costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily in T cells is considered a promising alternative approach to potentiate anti-tumor immunity that may complement strategies focused on the blockade of co-inhibitory pathways such PD-1/PDL1. Glucocorticoid-induced TNFR-related protein (GITR, CD357 or TNFRSF18) is an important T cell costimulatory receptor that can potentiate T cell receptor (TCR) signaling during CD4+ and CD8+ T cell priming, effector cell differentiat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 3 publications
0
1
0
Order By: Relevance
“…INCAGN01876 is an anti-GITR agonistic (IgG1) mAb developed with the aim of advancing malignancy treatment. INCAGN01876 without cross-reaction with other TNFR family members binds strongly to human and non-human primate GITR ( 261 ).…”
Section: Role In Cancermentioning
confidence: 99%
“…INCAGN01876 is an anti-GITR agonistic (IgG1) mAb developed with the aim of advancing malignancy treatment. INCAGN01876 without cross-reaction with other TNFR family members binds strongly to human and non-human primate GITR ( 261 ).…”
Section: Role In Cancermentioning
confidence: 99%